- Home
- BZAI vs CRVS Comparison
BZAI vs CRVS Comparison
Compare BZAI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAI
- CRVS
- Stock Information
- Founded
- BZAI 2010
- CRVS 2014
- Country
- BZAI United States
- CRVS United States
- Employees
- BZAI N/A
- CRVS N/A
- Industry
- BZAI
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- BZAI
- CRVS Health Care
- Exchange
- BZAI Nasdaq
- CRVS Nasdaq
- Market Cap
- BZAI 320.2M
- CRVS 459.0M
- IPO Year
- BZAI N/A
- CRVS 2016
- Fundamental
- Price
- BZAI $3.11
- CRVS $5.90
- Analyst Decision
- BZAI Strong Buy
- CRVS Strong Buy
- Analyst Count
- BZAI 2
- CRVS 4
- Target Price
- BZAI $8.00
- CRVS $15.00
- AVG Volume (30 Days)
- BZAI 1.2M
- CRVS 580.2K
- Earning Date
- BZAI 08-14-2025
- CRVS 08-07-2025
- Dividend Yield
- BZAI N/A
- CRVS N/A
- EPS Growth
- BZAI N/A
- CRVS N/A
- EPS
- BZAI N/A
- CRVS N/A
- Revenue
- BZAI $3,771,000.00
- CRVS N/A
- Revenue This Year
- BZAI $1,934.30
- CRVS N/A
- Revenue Next Year
- BZAI $346.90
- CRVS N/A
- P/E Ratio
- BZAI N/A
- CRVS N/A
- Revenue Growth
- BZAI 114.63
- CRVS N/A
- 52 Week Low
- BZAI $1.70
- CRVS $2.54
- 52 Week High
- BZAI $29.61
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- BZAI 39.29
- CRVS 65.25
- Support Level
- BZAI $3.28
- CRVS $5.58
- Resistance Level
- BZAI $3.30
- CRVS $5.99
- Average True Range (ATR)
- BZAI 0.27
- CRVS 0.32
- MACD
- BZAI -0.08
- CRVS 0.03
- Stochastic Oscillator
- BZAI 3.00
- CRVS 70.16
About BZAI Blaize Holdings Inc. Common Stock
Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).